Share on Facebook
Share on Twitter
Share on LinkedIn

The Food and Drug Administration approved label changes incorporating lower dosages for sleep medications containing zolpidem, a drug that can continue to affect patients’ mental alertness even a day after its use.

The regulator approved changes to the labels of Sanofi SA’s Ambien, Ambien CR and Meda AB’s Edluar on Tuesday.

Click here to read more.